[go: up one dir, main page]

AR037881A1 - Uso de derivados de oxindol - Google Patents

Uso de derivados de oxindol

Info

Publication number
AR037881A1
AR037881A1 ARP020104912A ARP020104912A AR037881A1 AR 037881 A1 AR037881 A1 AR 037881A1 AR P020104912 A ARP020104912 A AR P020104912A AR P020104912 A ARP020104912 A AR P020104912A AR 037881 A1 AR037881 A1 AR 037881A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
defined above
independently
3alkyl
Prior art date
Application number
ARP020104912A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR037881A1 publication Critical patent/AR037881A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de derivados de oxindol. Compuestos, proceso para su preparación e intermediarios utilizados en la preparación de los mismos. Composiciones farmacéuticas que contienen dichos compuestos terapéuticamente activos, y uso de dichos compuestos activos en terapia, especialmente, en la prevención y/o tratamiento de enfermedades relacionadas con demencia, mal de Alzheimer y condiciones asociadas con la quinasa 3 de sintasa de glucógeno. Reivindicación 1: Uso de un compuesto de fórmula (1), en donde: R1 es hidrógeno o alquilo C1-3; R2 es hidroxi, halógeno, trifluormetilo, ciano, amino, nitro, carboxi, alquilo C1-3, alcoxi C1-3, alcanoiloxi C1-3, alcanoílo C2-4, alcanoilamino C1-4, alcoxicarbonilo C1-4, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, carbamoílo, N-alquilcarbamoílo C1-4, N,N-di(alquilo C1-4)carbamoílo, aminosulfonilo, N-alquilaminosulfonilo C1-4, N,N-di(alquilo C1-4)aminosulfonilo, alquilsulfonilamino C1-4, o un grupo R4X1, en donde X1 es un enlace directo, alcanoíloC2-4, CONR5R6, SO2NR7R8, o SO2R9 (en donde R5 y R7 son cada uno de manera independiente, hidrógeno o alquilo C1-2, y R6, R8 y R9 son cada uno de manera independiente, alquilo C1-4, y en donde R4 está ligado a R6, R8 o R9); y R4 es fenilo o un grupo heterocíclico de 5 ó 6 miembros, con uno o dos heteroátomos, seleccionados en forma independiente entre O, S y N, cuyo grupo heterocíclico puede ser saturado o insaturado, y cuyo grupo fenilo o heterocíclico puede ser sustituido con uno o dos sustituyentes seleccionados de manera independiente entre hidroxi, halógeno, alquilo C1-3, alcoxi C1-3, alcanoiloxi C1-3, trifluormetilo, ciano, amino, nitro y alcoxicarbonilo C1-4; R3 es hidroxi, halógeno, trifluormetilo, alquilo C1-3, ciano, amino o R10X2, en donde X2 es O, CH2, S, SO, SO2, NR11CO, CONR12, SO2NR13, NR14SO2, o NR15 (en donde R11, R12, R13, R14 y R15 son cada uno de manera independiente, hidrógeno, alquilo C1-3 o alcoxi C1-3-alquilo C2-3, o X2 es un enlace directo; y R10 se selecciona entre uno de los siguientes grupos: 1) hidrógeno o alquilo C1-5 que puede ser sustituido con uno o más grupos seleccionados en forma independiente entre hidroxi, flúor y amino; 2) alquilo C1-5X3COR16 (en donde X3 es O ó NR17 (en donde R17 es hidrógeno, alquilo C1-3 o alcoxi C1-3alquiloC2-3) y R16 es alquilo C1-3 NR18R19 o OR20 (en donde R18, R19 y R20 son cada uno de manera independiente hidrógeno, alquilo C1-3 o alcoxi C1-3alquilo C2-3)); 3) alquilo C1-5X4R21 (en donde X4 es O, S, SO, SO2, OCO; NR22CO, CONR23, SO2NR24, NR25SO2 o NR26 (en donde R22, R23, R24, R25 y R26 son cada uno de manera independiente, hidrógeno, alquilo C1-3 o alcoxi C1-3alquilo C2-3) y R21 es hidrógeno, alquilo C1-3 ciclopentilo, ciclohexilo, o un grupo heterocíclico saturado de 5 ó 6 miembros con uno o dos heteroátomos seleccionados de manera independiente entre O, S y N, cuyo grupo alquilo C1-3 puede ser sustituido con uno o dos sustituyentes seleccionados en forma independiente entre oxo, hidroxi, halógeno y alcoxi C1-4, y cuyo grupo heterocíclico puede ser sustituido con uno o dos sustituyentes seleccionados en forma independiente entre oxo, hidroxi, halógeno, alquilo C1-4, hidroxialquilo C1-4 y alcoxi C1-4); 4) alquilo C1-5X5alquilo C1-5X6R27 (en donde X5 y X6 son cada uno de manera independiente O, S, SO, SO2, NR28CO, CONR29, SO2NR30, NR31SO2 o NR32 (en donde R28, R29, R30, R31 y R32 cada uno independientemente es hidrógeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R27 es hidrógeno o alquilo C1-3); 5) alquilo C1-5 R33 (en donde R33 es un grupo heterocíclico saturado de 5 ó 6 miembros, con uno o dos heteroátomos seleccionados de manera independiente entre O, S y N, cuyos grupos heterocíclico puede ser sustituido con uno o dos sustituyentes seleccionados en forma independiente entre oxo, hidroxi, halógeno, alquilo C1-4, carbonilo C1-6, hidroxialquilo C1-4 y alcoxi C1-4); 6) alquenilo C2-5 R33 (en donde R33 es como se define anteriormente); 7) alquinilo C2-5 R33 (en donde R33 es como se define anteriormente); 8) R34 (en donde R34 es un grupo piridona, un grupo fenilo o un grupo heterocíclico aromático de 5 ó 6 miembros con 1 a 3 heteroátomos seleccionados en forma independiente entre O, N y S, cuyo grupo piridona, fenilo o heterocíclico puede portar hasta 5 sustituyentes seleccionados en forma independiente entre hidroxi, halógeno, amino, alquilo C1-4, alcoxi C1-4, hidroxialquilo C1-4, aminoalquilo C1-4, alquilamino C1-4, hidroxialcoxi C1-4, carboxi, ciano, CONR35R36 y NR37COR38 (en donde R35, R36, R37 y R38 son cada uno, de manera independiente, hidrógeno, alquilo C1-4 o alcoxi C1-3 alquilo C2-3)); 9) alquilo C1-5 R34 (en donde R34 es como se define anteriormente); 10) alquenilo C2-5 R34 (en donde R34 es como se define anteriormente); 11) alquinilo C2-5 R34 (en donde R34 es como se define anteriormente); 12) alquilo C1-5 X7 R34 (en donde X7 es O, S, SO, SO2, NR39CO, CONR40, SO2NR41, NR42SO2 o NR43 (en donde R39, R40, R41, R42 y R43 cada uno de manera independiente es hidrógeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R34 es como se define anteriormente); 13) alquenilo C2-5 X8 R34 (en donde X8 es O, S, SO, SO2, NR44CO, CONR45, SO2NR46, NR47SO2 o NR48 (en donde R44, R45, R46, R47 y R48 cada uno de manera independiente es hidrógeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R34 es como se define anteriormente); 14) alquinilo C2-5 X9 R34 (en donde X9 es O, S, SO, SO2, NR49CO, CONR50, SO2NR51, NR52SO2, o NR53 (en donde R49, R50, R51, R52 y R53 cada uno de manera independiente es hidrógeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R34 es como se define anteriormente); 15) alquilo C1-3 X10 alquilo C1-3 R34 (en donde X10 es O, S, SO, SO2, NR54CO, CONR55, SO2NR56 NR57SO2, o NR58 (en donde R54, R55, R56, R57 y R58 cada uno de manera independiente es hidrógeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R34 es como se define anteriormente); 16) R33 (en donde R33 es como se define anteriormente); y 17) alquilo C1-3 X10 alquilo C1-3 R33 (en donde X10 y R33 son como se definen anteriormente); 18) alquilo C1-5 COR33 (en donde R33 es como se define anteriormente); n es 0, 1, 2, 3, ó 4; m es 0, 1, 2, 3, ó 4; como una base libre o una sal farmacéuticamente aceptable del mismo, en la elaboración de un medicamento para la prevención y/o tratamiento de condiciones asociadas con quinasa 3 de sintasa de glucógeno.
ARP020104912A 2001-12-21 2002-12-17 Uso de derivados de oxindol AR037881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34488701P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
AR037881A1 true AR037881A1 (es) 2004-12-09

Family

ID=23352491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104912A AR037881A1 (es) 2001-12-21 2002-12-17 Uso de derivados de oxindol

Country Status (11)

Country Link
US (2) US20050070559A1 (es)
EP (1) EP1458394B1 (es)
JP (2) JP4393196B2 (es)
AR (1) AR037881A1 (es)
AT (1) ATE411801T1 (es)
AU (1) AU2002359161A1 (es)
DE (1) DE60229554D1 (es)
ES (1) ES2314123T3 (es)
TW (1) TW200301123A (es)
UY (1) UY27592A1 (es)
WO (1) WO2003055492A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055877A1 (en) 2001-12-21 2003-07-10 Astrazeneca Ab Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
UY29198A1 (es) * 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007120102A1 (en) * 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2666590C (en) 2006-10-21 2015-10-06 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US20170209488A1 (en) 2014-07-17 2017-07-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN111936490A (zh) 2017-11-20 2020-11-13 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
EP3768267B1 (en) 2018-03-20 2025-05-14 Icahn School of Medicine at Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
JP2022515650A (ja) * 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
JP7416842B2 (ja) * 2022-02-18 2024-01-17 ナショナル ヘルス リサーチ インスティテューツ 縮合多環式化合物の調製方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ES2289791T3 (es) * 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
ATE288895T1 (de) * 1998-08-20 2005-02-15 Sumitomo Pharma Wachstumshormon-freisetzende oxindolderivate
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives

Also Published As

Publication number Publication date
US20050070559A1 (en) 2005-03-31
ATE411801T1 (de) 2008-11-15
US20090312322A1 (en) 2009-12-17
DE60229554D1 (de) 2008-12-04
JP2005516960A (ja) 2005-06-09
WO2003055492A1 (en) 2003-07-10
UY27592A1 (es) 2003-07-31
EP1458394A1 (en) 2004-09-22
ES2314123T3 (es) 2009-03-16
TW200301123A (en) 2003-07-01
JP2010013460A (ja) 2010-01-21
AU2002359161A1 (en) 2003-07-15
JP4393196B2 (ja) 2010-01-06
EP1458394B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
AR037881A1 (es) Uso de derivados de oxindol
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
AR038476A1 (es) Derivados de quinazolina
MA64853B1 (fr) N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
AR038052A1 (es) Derivados de quinazolina como inhibidores de auroraquinasas
DE69309492D1 (de) Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
GB9426103D0 (en) Therapeutic agents
SE0200979D0 (sv) New compounds
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
PA8561401A1 (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil) acetamida y procedimiento de produccion
GEP20063799B (en) Tropane derivatives useful in therapy
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
GEP20063751B (en) 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents
NO20014529D0 (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
SV2004001418A (es) Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248
BR0209518A (pt) Novos derivados arilheteroalquilamina
PE20240050A1 (es) Inhibidores de cdk2 y metodos de uso de los mismos
PT1758860E (pt) 3-piridil-benzocicloalquilmetil-aminas saturadas e insaturadas para utilização no tratamento da dor, depressões e estados de ansiedade
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
SE9702563D0 (sv) Compounds
BG106749A (en) Substituted homopiperidinyl benzimidazole analogues as fundic relaxants
DE60103034D1 (de) Neue phenylheteroalkylamin-derivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure